Valsartan
Valsartan. AT1 receptor blocker — no active metabolite (unlike losartan). Largely unchanged renal clearance; minimal CYP metabolism → fewer DDIs.… Oral half-life 7 h.
AT1 receptor blocker — no active metabolite (unlike losartan). Largely unchanged renal clearance; minimal CYP metabolism → fewer DDIs. Component of sacubitril/valsartan (Entresto) for HFrEF.
PK: THE CONTROL OF ITS GROUP, AND IT HOLDS — WHICH IS WORTH SAYING. F 0.23 is verbatim AND IS THE CAPSULE VALUE: "The fraction of dose absorbed and systemically available after oral administration was 0.23 for the capsule and 0.39 for the solution". The solution figure sits in the same sentence, and this record correctly did not take it — the exact trap candesartan fell into. The half-life is verbatim, the volume is verbatim ("The volume of distribution at steady state was 16.9 l") and INTRAVENOUS, so class 6 is acquitted. Valsartan is not a prodrug and needs no conversion, which is why it was chosen as the control. Only class 12 bites, mildly: 16.9 L on a 7.0 h terminal half-life implies 1.67 L/h against the same abstract verbatim "the total body clearance 2.2 l.h-1", 1.31x low, and the abstract names the cause itself — "biphasic decay kinetics, with a distribution phase (half-life 1.0 h)". The volume moves to the one that reproduces that clearance, keeping both the half-life and the clearance verbatim. ka 1.0 is replaced because absorption here is explicitly biphasic and 1.4 reproduces the verbatim "Plasma levels peaked 2 h after oral administration of the 80 mg capsule".
Pharmacokinetics
- Oral — t½ 7 h · F 23% · ka 1.436 h⁻¹ · Vd 22.2 L
Sources: PMID:8242249, PMID:9089423